Participating Faculty: Management of Patients With Homozygous Familial Hypercholesterolemia

Aegerion Pharmaceuticals, Inc

This supplement toThe American Journal of Managed Careprovides an overview of the pathophysiology, diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH), presents data for 2 recently approved orphan drugs for HoFH, and discusses considerations for managed care regarding this rare disease.This supplement was sponsored by, with editorial direction. Final content contained in this supplement was determined by the author and by the publishing staff ofThe American Journal of Managed Care.

FacultyPaul E. Ziajka, PhD

Director

Florida Lipid Institute

Winter Park, Florida

Faculty DisclosuresPaul E. Ziajka, PhD, reports relationships with the following organizations:

Grants: Genzyme

Honoraria: Aegerion Pharmaceuticals, Inc; AstraZeneca; GlaxoSmithKline; Merck

Signed disclosures are on file at the office ofThe American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Participating Faculty: Management of Patients With Homozygous Familial Hypercholesterolemia